[1] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪肝专家委员会.非酒精性脂肪性肝病防治指南 (2018年版).实用肝脏病杂志,2018,21(2):177-186. [2] Tamaki N, Munaganuru N,Jung JH,et al. Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease. Gut,2021,71(5):983-990. [3] 赵锦涵,张晶.代谢相关脂肪性肝病无创血清学诊断的研究进展.中华肝脏病杂志,2023,31(12):1235-1239. [4] Imajo K,Saigusa Y, Kobayashi T,et al. M-PAST score is better than MAST score for the diagnosis of active fibrotic nonalcoholic steatohepatitis. Hepatol Res,2023,53(9):844-856. [5] Newsome PN,Sasso M,Deeks JJ,et al. FibroScan-AST(FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol, 2020,5(4): 362-373. [6] 贾群玲,徐志宾,韩舒.非酒精性脂肪性肝病患者磁共振质子密度脂肪分数变化.实用肝脏病杂志,2021,24(3):359-362. [7] Abdel-Hameed EA,Rouster SD,Kottilil S,et al. The enhanced liver fibrosis index predicts hepatic fibrosis superior to FIB4 and APRI in HIV/HCV infected patients. Clin Infect Dis,2021,73(3):450-459. [8] Siddiqui MS,Yamada G,Vuppalanchi R,et al. Diagnostic accuracy of noninvasive fibrosis models to detect change in fibrosis stage. Clin Gastroenterol Hepatol,2019,17(9):1877-1885. [9] Pai RK,Jairath V,Hogan M,Zou G,et al. Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score. Hepatology,2022,76(4):1150-1163. [10] Brunt EM,Kleiner DE,Wilson LA,et al. Improvements in histologic features and diagnosis associated with improvement in fibrosis in nonalcoholic steatohepatitis: results from the nonalcoholic steatohepatitis clinical research network treatment trials. Hepatology,2019,70(2):522-531. [11] Wang J,Yan X,Zhu L,et al. Significant histological disease of patients with chronic hepatitis B virus infection in the grey zone. Aliment Pharm Ther, 2023,57(5):464-474. [12] Ji D,Chen Y,Shang Q,et al. Unreliable estimation of fibrosis regression during treatment by liver stiffness measurement in patients with chronic hepatitis B. Am J Gastroenterol,2021,116(8):1676-1685. [13] 阎道博,朱海超,闪海霞. 瞬时弹性成像联合APRI诊断自身免疫性肝炎患者肝纤维化效能研究.实用肝脏病杂志,2023,26(6):831-834. [14] Zhou J,Yan Feng,Xu JS,et al. Diagnosis of steatohepatitis and fibrosis in biopsy-proven nonalcoholic fatty liver diseases: including two-dimension real-time shear wave elastography and noninvasive fibrotic biomarker scores. Quant Imaging Med Surg, 2022,12(3):1800-1814. [15] Qu Y,Song YY,Chen CW,et al. Diagnostic performance of fibrotouch ultrasound attenuation parameter and liver stiffness measurement in asssessing hepatic steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Clin Transl Gastroenterol,2021,12(4):e00323. [16] Dennis A,Kelly MD,Fernandes C,et al. Correlations between MRI biomarkers PDFF and cT1 with histopathological features of non-alcoholic steatohepatitis. Front Endocrinol (Lausanne), 2021,11:575843. [17] Andersson A,Kelly M,Imajo K,et al. Clinical utility of magnetic resonance imaging biomarkers for identifying nonalcoholic steatohepatitis patients at high risk of progression: a multicenter pooled data and meta-analysis. Clin Gastroenterol H,2021,20(11):2451-2461. [18] Li J,Lu X,Zhu Z,et al. Head-to-head comparison of MR elastography-based liver stiffness, fat fraction and T1 relaxation time in identifying at-risk NASH. Hepatology,2023,78(4):1200-1208. [19] Oeda S,Takahashi H,Imajo K,et al. Diagnostic accuracy of Fibroscan-AST score to identify non-alcoholic steatohepatitis with significant activity and fibrosis in Japanese patients with non-alcoholic fatty liver disease comparison between M and XL probes. Hepatol Res,2020,50(7): 831-839. [20] Jung J,Loomba RR,Imajo K,et al. MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis. Gut,2020,70(10):1946-1953. |